REGENERON PHARMACEUTICALS, INC. Stock Issued During Period, Value, Conversion of Convertible Securities
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- REGENERON PHARMACEUTICALS, INC. stock issued during period, value, conversion of convertible securities for the quarter ending 2014-12-31 was $534.98M.
- REGENERON PHARMACEUTICALS, INC. stock issued during period, value, conversion of convertible securities for the quarter ending 2014-09-30 was $5.00K.
- REGENERON PHARMACEUTICALS, INC. stock issued during period, value, conversion of convertible securities for fiscal 2016 was $48.00M, a 94.13% decline from fiscal 2015.
- REGENERON PHARMACEUTICALS, INC. stock issued during period, value, conversion of convertible securities for fiscal 2015 was $818.36M, a 18.37% increase from fiscal 2014.
- REGENERON PHARMACEUTICALS, INC. stock issued during period, value, conversion of convertible securities for fiscal 2014 was $691.36M.
- REGENERON PHARMACEUTICALS, INC. stock issued during period, value, conversion of convertible securities for fiscal 2011 was $0.00.
| Period end | Stock Issued During Period, Value, Conversion of Convertible Securities 3 month | Stock Issued During Period, Value, Conversion of Convertible Securities 12 month |
|---|---|---|
| 2016-12-31 | $48.00M 10-K · filed 2019-02-07 | |
| 2015-12-31 | $818.36M 10-K · filed 2018-02-08 | |
| 2014-12-31 | $534.98M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-09 | $691.36M 10-K · filed 2017-02-09 |
| 2014-09-30 | $5.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | |
| 2011-12-31 | $0.00 10-K · filed 2012-02-21 | |
| 2010-12-31 | $0.00 10-K · filed 2012-02-21 | |
| 2009-12-31 | $0.00 10-K · filed 2012-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |